Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 14/20 | 0.40 |
| ▸ | CCR6 | P51684 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2017118 | 1.00 | GCK (0.40) | GCKCCR6NAMPTPRKAA2KCNH2 | |
| SCHEMBL2024523 | 0.96 | GCK (0.39) | GCKCCR6NAMPTPRKAA2KCNH2 | |
| SCHEMBL2024522 | 0.96 | GCK (0.39) | GCKCCR6NAMPTPRKAA2KCNH2 | |
| SCHEMBL2019938 | 0.93 | GCK (0.38) | GCKCCR6PRKAA2KCNH2 | |
| SCHEMBL1024633 | 0.93 | GCK (0.38) | GCKCCR6PRKAA2KCNH2 | |
| SCHEMBL1025560 | 0.92 | GCK (0.39) | GCKCCR6PRKAA2KCNH2 | |
| SCHEMBL2026821 | 0.92 | GCK (0.39) | GCKCCR6PRKAA2KCNH2 | |
| SCHEMBL2019241 | 0.91 | GCK (0.42) | GCKNAMPTKCNH2 | |
| SCHEMBL2019244 | 0.91 | GCK (0.42) | GCKNAMPTKCNH2 | |
| SCHEMBL2027043 | 0.91 | GCK (0.40) | GCKCCR6PRKAA2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275414-B1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | KYORIN SEIYAKU KK (JP) | 2015-06-10 | — | — | EP | claimed |
| US-8946440-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | claimed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | claimed |
| US-9452977-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-8946440-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | GCK 188/4885CCR6 2650/4885NAMPT 2062/4885 |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | GCK 188/4885CCR6 2650/4885NAMPT 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.